Shares of Daré Bioscience Inc. (DARE) were up 61.18% in pre-market trading as of the last check at $2.45. In yesterday’s session, shares of DARE dropped -3.90% at $1.52. DARE stock fluctuated between $1.46 and $1.60 during the day. There were 3.19 million shares traded, which is above DARE’s daily volume of 2.47 million over the last 50 days and its year-to-date volume of 2.55 million.
Shares of DARE stock have gained 50.50% in the last 12 months, but have declined -9.52% in the last week. For the past six months, DARE stocks have gained 16.03%, and for the past three months, the stock has declined -11.11%. DARE stock’s returns for this year have been 13.43%. DARE’s stock rose despite no current news, and we can then identify recent developments for a deeper analysis.
What happened recently at DARE?
Daré Bioscience develops innovative products for women’s health as a clinical-stage biopharmaceutical company. As part of its mission, DARE brings to market a wide range of differentiated therapies for women debating contraception, vaginal health, sexual health, and fertility.
The Phase 1 clinical trial of DARE-HRT1 by Daré Bioscience recently reported positive topline results.
- DARE-HRT1 is a new IVR technology that delivers bio-identical 17-estradiol and bio-identical progesterone continuously for 28 days as part of a hormone therapy (HT) regimen to treat vasomotor symptoms (VMS) and genitourinary syndrome associated with menopause.
- Two different active pharmaceutical ingredients were successfully delivered by DARE-HRT1 reliably over 28 days.
- It is a great achievement for Daré and for the IVR platform to generate positive topline data in its first Phase 1 study utilizing novel IVR technology.
- The use of hormone therapy for some women can relieve symptoms of menopause such as hot flashes and vaginal dryness while also preventing bone loss.
- The North American Menopause Society’s guidance on hormone therapy includes that dosing estrogen and progestogen in combination may offer important benefits to women and NAMS observed that non-oral routes of administration may offer advantages over orally administered therapies.
What DARE study has demonstrated?
Daré Bioscience (DARE) is encouraged by the Phase 1 results since these data demonstrate DARE-HRT1’s ability to meet its dual release objectives. IVR technology played a big role in DARE-HRT1’s success as it provides hormone therapy as well as platform technology. Compared to current vaginal drug delivery solutions, Dare-HRT1’s IVR technology may offer a more flexible and convenient way to deliver drugs to women as it allows them to release one or more drugs at a desired rate over time and at their convenience as well.
